NCT06904729 (CAR-T) is a Phase 3 clinical trial of Low-dose CAR-T cells group in Lupus Nephritis, sponsored by Guangzhou Women and Children's Medical Center.

Who is sponsoring NCT06904729?

NCT06904729 is sponsored by Guangzhou Women and Children's Medical Center.

What drugs are being tested in NCT06904729?

Interventions in NCT06904729: Low-dose CAR-T cells group, High-dose CAR-T cells group.

What condition does NCT06904729 study?

NCT06904729 studies Lupus Nephritis.

Is NCT06904729 still recruiting?

NCT06904729 is currently recruiting now. Last updated 1 April 2025.

Last reviewed 2025-04-01 · How we verify

NCT06904729: CAR-T

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in Children

Recruiting now Phase 3 Last updated 1 April 2025

What this trial tests

Phase 3 trial testing Low-dose CAR-T cells group in Lupus Nephritis in 50 participants. Currently enrolling.

Timeline

1 May 2025

Primary endpoint
30 April 2029

30 April 2029

Quick facts

Lead sponsor	Guangzhou Women and Children's Medical Center
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	1 May 2025
Primary completion	30 April 2029
Estimated completion	30 April 2029
Sites	1 location across China

Drugs / interventions tested

Low-dose CAR-T cells group — full drug profile →
High-dose CAR-T cells group — full drug profile →

Conditions studied

Lupus Nephritis — all drugs for Lupus Nephritis →

Sponsor

Guangzhou Women and Children's Medical Center

Who can join

Adults 6 to 18, any sex, with Lupus Nephritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this prospective, open, single-arm clinical trial was to evaluate the safety and potential efficacy of CAR T cell therapy in children with refractory/recurrent lupus nephritis. The persistence and cell phenotype of CAR-T cells in vivo and CAR-T treatment-related inflammatory factors were evaluated after treatment. To explore new therapeutic methods, in order to reduce the side effects of traditional therapeutic drugs, increase curative effect, and finally make patients obtain long-term survival and improve survival quality.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Innovations in immunotherapy for autoimmune diseases: recent breakthroughs and future directions.
Alsayb MA. · · 2025 · cited 2× · PMID 41041324 · DOI 10.3389/fimmu.2025.1647066
Roads and detours for CAR T cell therapy in autoimmune diseases.
Avouac J, Barzel A, Caiati D, Davis RS, et al · · 2026 · cited 1× · PMID 41588112 · DOI 10.1038/s41573-025-01349-4
Juvenile-onset Systemic Lupus Erythematosus: Recent Advances in Pathogenesis and Treatment.
Natoli V, Charras A, Smith EM, Hedrich CM. · · 2025 · cited 1× · PMID 41410901 · DOI 10.1007/s11926-025-01207-7
Global perspectives on lupus nephritis: a review of clinical trials and therapeutic innovations.
Xu J, Zhang Y, Huang H, Cao Y. · · 2026 · PMID 42233033 · DOI 10.3389/fimmu.2026.1762892
Chimeric antigen receptor T-cell therapy in pediatric neurological autoimmune diseases: mechanisms, clinical applications, and future perspectives.
Ling W, Xu C, Tang J, Lu S, et al · · 2026 · PMID 41960033 · DOI 10.3389/fped.2026.1740566
The evolving landscape of rheumatic drugs and their indications in paediatric and adolescent care.
Ciurtin C, Sparchez M, Elephtheriou D, Brogan P. · · 2025 · PMID 40845184 · DOI 10.1093/rheumatology/keaf455

Verify or expand the search:

Other recruiting trials for Lupus Nephritis

Currently open trials in the same condition.

NCT07523542 — SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus · Phase 1, PHASE2 · recruiting
NCT07109986 — UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis · Phase 1 · recruiting
NCT07053891 — LUPKYNIS Drug-use Results Survey · recruiting
NCT07015983 — A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite I · Phase 2 · recruiting
NCT06711887 — Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants · Phase 3 · recruiting

Other Guangzhou Women and Children's Medical Center trials

Trials by the same sponsor.

NCT07190001 — YOLT-204 in Patients With Hemoglobinopathies · EARLY_PHASE1 · not yet recruiting
NCT06948994 — A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Di · Phase 1, PHASE2 · not yet recruiting
NCT06856759 — Single-Dose AAV-MECP2 Safety/Tolerability and Efficacy in Rett Syndrome · EARLY_PHASE1 · recruiting
NCT06731205 — Long-term Renal Prognosis of Neonatal Acute Kidney Injury · not yet recruiting
NCT06731192 — Human Umbilical Cord Mesenchymal Stem Cells for Alport Syndrome · Phase 2, PHASE3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06904729 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangzhou Women and Children's Medical Center
Last refreshed: 1 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06904729.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing